LY-503430

LY-503430 is an AMPA receptor positive allosteric modulator developed by Eli Lilly.^[1]

Other namesLY-503430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide

Routes of
administrationOral

Legal status

• US: Investigational New Drug

CAS Number

• 625820-83-9 ^Y

Quick facts Clinical data, Other names ...

LY-503430

Clinical data
Other names	LY-503430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide
Routes of administration	Oral
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name 4'-{(1S)-1-fluoro-2-[(isopropylsulfonyl)amino]-1-methylethyl}-N-methylbiphenyl-4-carboxamide
CAS Number	625820-83-9 Y
PubChem CID	9952446
ChemSpider	8128056 N
UNII	3NKZ7DGF3R
Chemical and physical data
Formula	C20H25FN2O3S
Molar mass	392.49 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)S(=O)(=O)NCC(F)(C)c(cc2)ccc2-c(cc1)ccc1C(=O)NC
InChI InChI=1S/C20H25FN2O3S/c1-14(2)27(25,26)23-13-20(3,21)18-11-9-16(10-12-18)15-5-7-17(8-6-15)19(24)22-4/h5-12,14,23H,13H2,1-4H3,(H,22,24)/t20-/m0/s1 N Key:MFJKNXILEXBWNQ-FQEVSTJZSA-N N
NY (what is this?)  (verify)

Close

LY-503430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus, and striatum.^[2][3] It is orally active and the main application it is currently being developed for is treatment of Parkinson's disease, although it has also been proposed to be useful in the treatment of Alzheimer's disease, depression, and schizophrenia.^[4][5]